keyword
MENU ▼
Read by QxMD icon Read
search

PDL-1

keyword
https://www.readbyqxmd.com/read/29463302/the-impact-of-pd-l1-on-survival-and-value-of-the-immune-check-point-inhibitors-in-non-small-cell-lung-cancer-proposal-policies-and-perspective
#1
Helmy M Guirgis
BACKGROUND: The impact of programmed death receptor-ligand1 (PD-L1) on costs and value of the immune check point inhibitors (ICPI) has received minimal attention. OBJECTIVES: 1- Design a sliding scale to grade survival in 2nd-line non-small-cell lung cancer (NSCLC). 2- Compare costs and value of Nivolumab (Nivo), Atezolizumab (Atezo) and Pembrolizumab (Pembro) vs. Docetaxel (Doc). METHODS: Previously reported median overall survival (OS) and prices posted by parent company were utilized...
February 20, 2018: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29439008/pd-1-and-pd-l1-expression-in-thymic-epithelial-tumours-and-non-neoplastic-thymus
#2
Emine Kilic Bagir, Arbil Acikalin, Alper Avci, Derya Gumurdulu, Semra Paydas
AIMS: We explored the relationships between programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression and the pathological and clinical features of thymic epithelial tumours and thymic hyperplasia. METHODS: We evaluated PD-1 and PDL-1 expressions within epithelial and microenvironmental components in thymic epithelial tumours (n=44) and thymic hyperplasias (n=8), immunohistochemically. We compared the results with demographic, clinical and histopathological features of the cases...
February 8, 2018: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/29368051/role-of-immunotherapy-in-bladder-cancer-past-present-and-future
#3
REVIEW
Sabeeh-Ur-Rehman Butt, Laeeq Malik
As research focus in oncology has recently shifted from oral targeted therapy to immunomodulation, the era of successful drug development in bladder cancer has just begun. This has led to unprecedented approval of five immunotherapeutic agents by regulatory agencies for metastatic bladder cancer within a span of 12 months. With an initial triumph of anti-programmed cell death-1 (anti-PD-1) and anti-programmed cell death ligand-1 (anti-PDL-1) drugs, ongoing efforts are aimed at identification and validation of new druggable immune targets to consolidate the initial gains...
January 24, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29362129/proportion-of-cd4-and-cd8-tumor-infiltrating-lymphocytes-predicts-survival-in-persistent-recurrent-laryngeal-squamous-cell-carcinoma
#4
Rebecca Hoesli, Andrew C Birkeland, Andrew J Rosko, Mohamad Issa, Kelsey L Chow, Nicole L Michmerhuizen, Jacqueline E Mann, Steven B Chinn, Andrew G Shuman, Mark E Prince, Gregory T Wolf, Carol R Bradford, Jonathan B McHugh, J Chad Brenner, Matthew E Spector
Tumor infiltrating lymphocytes (TILs) have been shown to be an important prognostic factor in patients with previously untreated head and neck cancer. After organ preservation therapy for laryngeal cancer and subsequent persistence/recurrence, the prognostic value of TILs is unknown. Our goal was to determine if TILs have value as a prognostic biomarker in patients with surgically salvageable persistent/recurrent laryngeal squamous cell carcinoma. Levels of TILs were quantified on tissue microarrays from 183 patients undergoing salvage total laryngectomy for persistent/recurrent laryngeal cancer after radiation or chemoradiation between 1997 and 2014...
February 2018: Oral Oncology
https://www.readbyqxmd.com/read/29344157/expression-and-clinical-significance-of-programmed-death-1-on-lymphocytes-and-programmed-death-ligand-1-on-monocytes-in-the-peripheral-blood-of-patients-with-cervical-cancer
#5
Ying Zhang, Weipei Zhu, Xueguang Zhang, Qiuxia Qu, Liyuan Zhang
The programmed death-1 (PD-1) signaling pathway serves a critical role in immune regulation and tolerance by suppressing the activation and proliferation of T cells. The aim of the present study was to investigate the effect of PD-1 and programmed death-ligand 1 (PD-L1) on the development of cervical carcinoma and cervical intraepithelial neoplasia (CIN). A total of 40 healthy controls (HC), 40 patients with CIN and 66 newly diagnosed cervical cancer patients were recruited. The expression level of PD-1 expression on peripheral cluster of differentiation (CD)4+ and CD8+ T cells and PD-L1 on monocytes was analyzed by flow cytometry...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29321652/innate-ifn-%C3%AE-ameliorates-experimental-autoimmune-encephalomyelitis-and-promotes-myeloid-expansion-and-pdl-1-expression
#6
Madeleine P J White, Gill Webster, Faith Leonard, Anne Camille La Flamme
The innate immune system plays a central role in the immune-mediated pathology of multiple sclerosis, and is a therapeutic target for progressive disease. Recently, it has been demonstrated that MIS416, a novel immunomodulatory microparticle that activates NOD-2 and TLR-9-signaling, has disease-modifying activity in multiple sclerosis models. This activity is dependent on innate IFN-γ; however, the precise immune regulatory mechanisms amplified by MIS416 have not previously been determined. Using the experimental autoimmune encephalomyelitis model, MIS416 treatment was associated with IFN-γ-dependant expansion of Treg number and increased suppressive function; however, these cells did not account for disease reduction...
January 10, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29228684/atorvastatin-downregulates-co-inhibitory-receptor-expression-by-targeting-ras-activated-mtor-signalling
#7
Isobel Okoye, Afshin Namdar, Lai Xu, Nicole Crux, Shokrollah Elahi
Regulation of T cell function in the steady state is mediated by co-inhibitory receptors or immune checkpoints such as PD-1, CTLA-4, TIM-3 and LAG-3. Persistent antigen stimulation, during chronic viral infections and cancer, results in sustained expression of multiple co-inhibitory receptors and subsequently poor effector T cell function. Immune checkpoint blockade using monoclonal antibodies against PD-1, PDL-1 and CTLA-4 has been implemented as an immunotherapy strategy- resulting in restoration of T cell function and reduction of viral load or tumour growth...
November 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29182990/patterns-of-responses-in-metastatic-nsclc-during-pd-1-or-pdl-1-inhibitor-therapy-comparison-of-recist-1-1-irrecist-and-irecist-criteria
#8
M Tazdait, L Mezquita, J Lahmar, R Ferrara, F Bidault, S Ammari, C Balleyguier, D Planchard, A Gazzah, J C Soria, A Marabelle, B Besse, C Caramella
BACKGROUND: Immune checkpoint inhibitors are an important tool in the therapeutic strategy against metastatic non-small cell lung cancer (NSCLC); however, radiological evaluation is challenging due to the emergence of atypical patterns of responses. Several evaluation criteria have been proposed, such as the Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1, immune -related RECIST (irRECIST) and iRECIST, but have not been systematically compared in a homogeneous population...
January 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29180896/checkpoint-blockade-in-solid-tumors-and-b-cell-malignancies-with-special-consideration-of-the-role-of-cd200
#9
REVIEW
Reginald M Gorczynski, Fang Zhu
In the ontogeny of a normal immune response, a series of checkpoints must be overcome to ensure that unwanted and/or harmful self-directed activation responses are avoided. Many of the molecules now known to be active in this overseeing of the evolving immune activation cascade, contributing inhibitory signals to dampen an overexuberant response, belong to the immunoglobulin supergene family. These include members of the CD28/CTLA-4:B7.1/B7.2 receptor/ligand family, PD-1 and PDL-1, CD200 and CD200R, and the more recently described V-domain immunoglobulin suppressor of T-cell activation and its ligand (VSIG-3/IGSF11)...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/29150026/regulatory-t-cells-friends-or-foe-in-human-mycobacterium-leprae-infection
#10
Ana T Chaves, Atvaldo F Ribeiro-Junior, Sandra Lyon, Nayara I Medeiros, Fábio Cassirer-Costa, Karina S Paula, Edilamar S Alecrim, Cristiane A S Menezes, Rodrigo Correa-Oliveira, Manoel O C Rocha, Juliana A S Gomes
Regulatory T cells (Tregs) are known to control immune responses by suppressing the antigen-presenting and effector T cells. Some mechanisms adopted by Tregs in combating Mycobacterium infections have been proposed. Nevertheless, in M. leprae infection, also known as leprosy or Hansen's disease, the role of Tregs has not been completely elucidated. Using multicolor flow cytometry, we evaluated the expression of different cell surface and intracellular molecules present in Tregs from peripheral blood samples of leprosy patients...
November 13, 2017: Immunobiology
https://www.readbyqxmd.com/read/29117898/the-contribution-of-immune-infiltrates-and-the-local-microenvironment-in-the-pathogenesis-of-osteosarcoma
#11
Marie-Françoise Heymann, Frédéric Lézot, Dominique Heymann
Osteosarcoma is a rare primary bone cancer characterized by cancer cells producing calcified osteoid extracellular matrix and inducing lung metastases with a high frequency. The local microenvironment defined several tumor niches controlling the tumor growth and cell extravasation. The immune infiltrate composes one of these niches. The immune environment of osteosarcoma is mainly composed by T-lymphocytes and macrophages but also contains other subpopulations including B-lymphocytes and mast cells. Osteosarcoma cells control the recruitment and differentiation of immune infiltrating cells and establish a local immune tolerant environment favorable to the tumor growth, drug resistance and the occurrence of metastases...
November 2, 2017: Cellular Immunology
https://www.readbyqxmd.com/read/29070883/combined-immunotherapy-with-anti-pdl-1-pd-1-and-anti-cd4-antibodies-cures-syngeneic-disseminated-neuroblastoma
#12
Valentina Rigo, Laura Emionite, Antonio Daga, Simonetta Astigiano, Maria Valeria Corrias, Concetta Quintarelli, Franco Locatelli, Silvano Ferrini, Michela Croce
Anti-PD-1 or anti-PD-L1 blocking monoclonal antibodies (mAbs) have shown potent anti-tumor effects in adult cancer patients and clinical studies have recently been started in pediatric cancers, including high-risk/relapsing neuroblastoma (NB). Therefore, we studied the effects of anti-PD-1/PD-L1 mAbs in two syngeneic models of disseminated NB generated by the injection of either Neuro2a or NXS2 cells, which express PD-L1. In addition, we tested the combination of these agents with the immune-enhancing cytokine IL-21, the Ecto-NTPDase inhibitor POM-1, an anti-CD25 mAb targeting Treg cells, or an anti-CD4 mAb...
October 25, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29055015/small-molecule%C3%A2-inhibition-of-pd-1-transcription-is-an-effective-alternative-to-antibody-blockade-in-cancer-therapy
#13
Alison Taylor, David Rothstein, Christopher E Rudd
The impact of PD-1 immune checkpoint therapy prompts exploration of other strategies to downregulate PD-1 for cancer therapy. We previously showed that the serine/threonine kinase, glycogen synthase kinase GSK-3α/β, is a central regulator of PD-1 transcription in CD8+ T cells. Here, we show that the use of small molecule inhibitors of GSK-3α/β (GSK-3i) to reduce pcdc1 (PD-1) transcription and expression was as effective as anti-PD-1 and PDL-1 blocking antibodies in the control of B16 melanoma, or EL4 lymphoma, in primary tumor and metastatic settings...
October 20, 2017: Cancer Research
https://www.readbyqxmd.com/read/28971402/-mir-140-3p-downregulation-in-association-with-pdl-1-overexpression-in-many-cancers-a-review-from-the-literature-using-predictive-bioinformatics-tools
#14
Nikolaos Kapodistrias, Catherine Bobori, Georgia Theocharopoulou
Programmed death-ligand 1 (PD-L1) has been speculated to play a critical role in suppression of the immune system and it can be upregulated in cancer cells, which may allow cancers to evade the host immune system. MicroRNAs (miRNAs) are small non-coding RNA molecules (containing about 22 nucleotides), that function in RNA silencing and post-transcriptional regulation of gene expression. MiRNAs were found deregulated (upregulated or downregulated) and implicated in cancer development with various roles which depend on their gene target...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28932633/cd163-positive-tumor-associated-macrophages-and-cd8-positive-cytotoxic-lymphocytes-are-powerful-diagnostic-markers-for-the-therapeutic-stratification-of-osteosarcoma-patients-an-immunohistochemical-analysis-of-the-biopsies-fromthe-french-os2006-phase-3-trial
#15
Anne Gomez-Brouchet, Claire Illac, Julia Gilhodes, Corinne Bouvier, Sébastien Aubert, Jean-Marc Guinebretiere, Béatrice Marie, Frédérique Larousserie, Natacha Entz-Werlé, Gonzague de Pinieux, Thomas Filleron, Véronique Minard, Vincent Minville, Eric Mascard, François Gouin, Marta Jimenez, Marie-Cécile Ledeley, Sophie Piperno-Neumann, Laurence Brugieres, Françoise Rédini
The French phase 3 trial (OS 2006) testing zoledronic acid, an osteoclast inhibitor, with chemotherapy and surgery did not improve the outcome of patients with osteosarcoma (OS). To understand this unexpected result, the presence of infiltrating immune cells was investigated in 124 pre-therapeutic biopsies of patients enrolled in the trial. The percentage of CD68/CD163 tumor-infiltrating macrophages (TAMs), CD8(+) lymphocytes, osteoclasts, and the PD1/PDL-1 checkpoint were assessed by immunohistochemistry. M1/M2 macrophage polarization was characterized by pSTAT1/CMAF staining...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28878676/pd-1-and-pd-l1-checkpoint-signaling-inhibition-for-cancer-immunotherapy-mechanism-combinations-and-clinical-outcome
#16
REVIEW
Hashem O Alsaab, Samaresh Sau, Rami Alzhrani, Katyayani Tatiparti, Ketki Bhise, Sushil K Kashaw, Arun K Iyer
Several cancers are highly refractory to conventional chemotherapy. The survival of tumors in several cases is assisted by checkpoint immunomodulation to maintain the imbalance between immune surveillance and cancer cell proliferation. Check point antibody inhibitors, such as anti-PD-1/PD-L1, are a novel class of inhibitors that function as a tumor suppressing factor via modulation of immune cell-tumor cell interaction. These checkpoint blockers are rapidly becoming a highly promising cancer therapeutic approach that yields remarkable antitumor responses with limited side effects...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28869918/circulating-cd4-pd-1-and-cd8-pd-1-t-cells-are-profoundly-decreased-at-the-onset-of-fulminant-type-1-diabetes-and-are-restored-by-treatment-contrasting-with-cd4-cd25-foxp3-regulatory-t-cells
#17
Toshie Iijima, Kanako Kato, Teruo Jojima, Takanori Tomotsune, Maiko Fukushima, Kunihiro Suzuki, Yoshimasa Aso
Programed cell death protein-1 (PD-1) is an inhibitory receptor expressed by T cells that downregulates the activation and proliferation of these cells to maintain peripheral self-tolerance. Recent studies reported some cases of new-onset type 1 diabetes (T1D) under anti-PD1 or PDL-1 antibodies. We demonstrated that circulating both CD4+PD-1+ and CD8+PD-1+ T cells were profoundly reduced at the onset of fulminant T1D and were restored by treatment in two patients with fulminant T1D.
July 31, 2017: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/28855904/immunological-properties-of-murine-parthenogenetic-stem-cell-derived-cardiomyocytes-and-engineered-heart-muscle
#18
Michael Didié, Satish Galla, Vijayakumar Muppala, Ralf Dressel, Wolfram-Hubertus Zimmermann
Pluripotent parthenogenetic stem cells (pSCs) can be derived by pharmacological activation of unfertilized oocytes. Homozygosity of the major histocompatibility complex (MHC) in pSCs makes them an attractive cell source for applications in allogeneic tissue repair. This was recently demonstrated for pSC-based tissue-engineered heart repair. A detailed analysis of immunological properties of pSC-derived cardiomyocytes and engineered heart muscle (EHM) thereof is, however, lacking. The aim of this study was to determine baseline and cytokine-inducible MHC class I and MHC class II as well as programmed death ligand-1 (PDL-1) and co-stimulatory protein (CD40, CD80, CD86) expression in pSC-derived cardiomyocytes and pSC-EHM in vitro and in vivo...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28831825/pdl-1-pd1-inhibitors-antibody-or-antinobody
#19
EDITORIAL
Fouad Aoun, Elie El Rassy, Tarek Assi, Joseph Kattan
No abstract text is available yet for this article.
August 2017: Future Oncology
https://www.readbyqxmd.com/read/28815334/clinical-characteristics-of-patient-selection-and-imaging-predictors-of-outcome-in-solid-tumors-treated-with-checkpoint-inhibitors
#20
REVIEW
Sabrina Rossi, Luca Toschi, Angelo Castello, Fabio Grizzi, Luigi Mansi, Egesta Lopci
The rapidly evolving knowledge on tumor immunology and the continuous implementation of immunotherapy in cancer have recently led to the FDA and EMA approval of several checkpoint inhibitors as immunotherapic agents in clinical practice. Anti-CTLA-4, anti-PD-1, and anti-PDL-1 antibodies are becoming standard of care in advanced melanoma, as well as in relapsed or metastatic lung and kidney cancer, demonstrating higher and longer response compared to standard chemotherapy. These encouraging results have fostered the evaluation of these antibodies either alone or in combination with other therapies in several dozen clinical trials for the treatment of multiple tumor types...
December 2017: European Journal of Nuclear Medicine and Molecular Imaging
keyword
keyword
49553
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"